following a full submission:
ixekizumab (Taltz®) is accepted for restricted use within NHS Scotland.
Indication under review: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Ixekizumab was superior to placebo and to a tumour necrosis factor (TNF) antagonist for improving symptoms of adults with moderate to severe plaque psoriasis.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ixekizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice262KB (PDF)
Medicine details
- Medicine name:
- ixekizumab (Taltz)
- SMC ID:
- 1223/17
- Indication:
- Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 April 2017